Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Malawi and Tanzania launch national "provided-initiated" HIV screening:

This article was originally published in Clinica

Executive Summary

The government of Malawi is calling on the sexually-active of its population to test for HIV. The move is in response to an acknowledged lack of control of the disease and a need for better data to support prevention planning. Estimates put national prevalence at around 14% of the country's 12 million population; only 15% of the country's six million sexually-active population are thought to know their HIV status. The programme will also adopt guidance issued recently by the WHO on conducting "provider-initiated" voluntary testing, from which the patient has to actively opt out (see Clinica No 1259, p 9). Around 80% of people with HIV in sub-Saharan Africa are unaware of being infected, the WHO estimates. Tanzania, too, has just launched a national HIV-testing programme based on this guidance, Clinica understands.

You may also be interested in...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts